Resultados de Búsqueda

NICE

National Institute for Health and Clinical Excellence (NICE)

Evidence shows that there are serious complications and that it provides no benefit.

NICE

National Institute for Health and Clinical Excellence (NICE)

There are currently no disease-modifying treatments available for primary progressive multiple sclerosis. Results of 1 clinical trial show that ocrelizumab can slow the worsening of disability, although the size and duration of this effect are uncertain. Given the unmet clinical need, the most plausible cost-effectiveness estimates for ocrelizumab at the agreed price compared with best supportive care alone are in the range that NICE considers an acceptable use of NHS resources. Because of ...

NICE

National Institute for Health and Clinical Excellence (NICE)

This recommendation is not intended to affect treatment with cladribine that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Highly active relapsing–remitting multiple sclerosis is currently treated with alemtuzumab, fingolimod or natalizumab. This ...

NICE

National Institute for Health and Care Excellence

Treatments for recurrent non-infectious uveitis affecting the posterior segment of the eye include systemic corticosteroids, immunosuppressants and dexamethasone implants. These treatments can be disruptive to daily life, needing frequent hospital visits. The clinical trial results for the fluocinolone acetonide intravitreal implant compared with limited current practice are difficult to interpret and very uncertain. The trial didn't directly measure health-related quality of life and the ...

NICE

National Institute for Health and Care Excellence

Research should ideally take the form of randomised controlled trials comparing this procedure with standard therapies and should report safety events and long-term outcomes. NICE may update the guidance on publication of further evidence.